Clinical trials
Completed Pneumonia, Ventilator-Associated trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 38 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 4 |
| Centre Hospitalier Departemental Vendee | 3 |
| University Hospital, Lille | 3 |
| Centre Hospitalier Universitaire de Nīmes | 2 |
| Nantes University Hospital | 2 |
| Shionogi | 2 |
| University Hospital, Bordeaux | 2 |
| Université Victor Segalen Bordeaux 2 | 2 |
| Aridis Pharmaceuticals, Inc. | 1 |
| Centre Chirurgical Marie Lannelongue | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pneumonia, Ventilator-Associated | 38 |
| Pneumonia | 8 |
| Healthcare-Associated Pneumonia | 6 |
| Pseudomonas Infections | 3 |
| Acute Lung Injury | 2 |
| Bacterial Infections | 2 |
| COVID-19 | 2 |
| Cross Infection | 2 |
| Disease | 2 |
| Pneumonia, Bacterial | 2 |
Trials
Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.